EGF

100% Secure

No associated image currently available

Recombinant Human EGF

Product Type: Recombinant Protein

Product Code	Applications	Pack Size	Your Price	List Price	Quantity
PHP030A Datasheet	E FN WB SDS	0.5 mg	Log in		Get Quote

Recombinant human epidermal growth factor is 6.2kDa globular protein comprosed of 53 amino acids. EGF is a polypeptide growth factor which stimulates the proliferation of a wide range of epidermal and epithelial cells.

Product Details

Target Species

Human

Species Cross-Reactivity

Target Species	Cross Reactivity
Mouse

N.B. Antibody reactivity and working conditions may vary between species.

Product Form

Purified recombinant protein - lyophilized

Reconstitution

Reconstitute with 0.5ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. For extended storage, the addition of 5% trehalose is recommended

Preparation

Purified recombinant human EGF expressed in E. coli

Preservative Stabilisers

None present

Carrier Free

Yes

Activity

1 x 10⁷ units/mg

Purity

>98% by SDS PAGE and HPLC analysis

Approx. Protein Concentrations

1.0 mg/ml after reconstitution.

Protein Molecular Weight

6.2 kD (53 Amino acid sequence)

Endotoxin Level

< 0.1 ng/ug

Storage Information

Storage: Prior to reconstitution store at -20^oC. Following reconstitution store at -20^oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee: Guaranteed for 3 months from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

More Information

UniProt: P01133
Entrez Gene: EGF
GO Terms: GO:0005886 plasma membrane; GO:0006260 DNA replication; GO:0005509 calcium ion binding; GO:0001525 angiogenesis; GO:0002576 platelet degranulation; GO:0016021 integral to membrane; GO:0005154 epidermal growth factor receptor binding; GO:0030297 transmembrane receptor protein tyrosine kinase activator activity; GO:0045741 positive regulation of epidermal growth factor receptor activity; GO:0007173 epidermal growth factor receptor signaling pathway; GO:0008083 growth factor activity; GO:0030168 platelet activation; GO:0031093 platelet alpha granule lumen; GO:0035413 positive regulation of catenin import into nucleus; GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway; GO:0043406 positive regulation of MAP kinase activity; GO:0045840 positive regulation of mitosis; GO:0051048 negative regulation of secretion; GO:0090279 regulation of calcium ion import; GO:2000008 regulation of protein localization at cell surface
Regulatory: For research purposes only

Applications of EGF

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

Application Name	Min Dilution	Max Dilution
ELISA	0.2	0.4ng/well
Functional Assays	0.5	25ng/ml
Western Blotting	1.5	3.0ng/lane

Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate postive/negative controls.

ELISA: Recombinant human EGF may be used as athe standard in ELISA applications with either a purified human EGF antibody (AHP767) or a biotinylated human EGF antibody (AHP767B).
Western Blotting: Recombinant human EGF may be used as the positive control for Wester Blotting application with either a purified human EGF antibody (AHP767) or a biotinylated human EGF antibody (AHP767B)

Product Specific References

References for EGF

Tomlins, C. & Storey, A. (2010) Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis.
Carcinogenesis. 31 (12): 2155-64.
Wray, H. et al. (2012) α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis.
PLoS One. 7 (10): e46968.
Chen, W. et al. (2016) Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
PLoS One. 11 (11): e0166268.
Zhang, X. et al. (2015) Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells.
Med Oncol. 32 (4): 95.
Roth, K. et al. (2021) Clinically relevant aberrant Filip1l DNA methylation detected in a murine model of cutaneous squamous cell carcinoma.
EBioMedicine. 67: 103383.
Inman, G.J. et al. (2018) The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
Nat Commun. 9 (1): 3667.
Aiderus, A. et al. (2021) Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.
PLoS Genet. 17 (8): e1009094.

Fluorescent Spectraviewer

Watch the Tool Tutorial Video ▸

How to Use the Spectraviewer